Search Clinical Trials
Completed
Nitric Oxide Production in MELAS Syndrome (External Link)
What does the study involve? Individuals with MELAS syndrome will be admitted twice to the General Clinical Research Center (GCRC) at Texas Children's Hospital. Each time they will stay for …
Baylor Role:
Lead Sponsor
Completed
Amitiza in Constipation Associated With PD (Parkinson's Disease) (External Link)
Parkinson's disease (PD) affects about one million people in the United States. It is a common neurological condition that is clinically defined by rigidity (muscle stiffness), bradykinesia (slowness of movement) …
Baylor Role:
Lead Sponsor
Completed
Nutritional Status and Enteral Absorption Capability After Brain Death (External Link)
There are an estimated 98,000 people in need of organ transplants in the United States (OPTN). Only a fraction of the need is met with the organs that become available. …
Baylor Role:
Collaborator
Completed
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury (External Link)
Traumatic brain injury (TBI) is a leading cause of death and disability among young adults. Mood disorders are the most frequent psychiatric complication of TBI, and have a large impact …
Baylor Role:
Lead Sponsor
Completed
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder (External Link)
The cause of liver damage in people with ASA is unknown. However, because ASA is the only urea cycle disorder that is characterized by both liver damage and elevated levels …
Completed
Cognitive Behavior Therapy for Treating Anxiety in People With Dementia (External Link)
Dementia is an illness that causes memory problems; changes in behavior; and difficulty with thinking, making decisions, and carrying out daily activities. Many people with dementia also have anxiety, and …
Baylor Role:
Lead Sponsor
Completed
Selegiline to Zelapar Switch Study in Parkinson Disease Patients (External Link)
This is an open label, multicenter, 6 week study of the conversion from oral selegiline to orally disintegrating selegiline in PD patients with or without motor fluctuations, and currently taking …
Baylor Role:
Lead Sponsor
Completed
Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study (External Link)
This is a study to compare orally dissolving levodopa (Parcopa) to the conventional immediate release oral levodopa. This is a single-dose, double-blind, placebo controlled crossover trial in participants with Parkinson …
Baylor Role:
Lead Sponsor
Completed
Dietary Supplements for the Treatment of Angelman Syndrome (External Link)
AS is a neurologic disorder that may cause developmental delay, mental retardation, severe speech impairment, seizures, small head size, and problems with movement and balance in young children. AS is …
Baylor Role:
Collaborator
Completed
Pregabalin in the Treatment of Essential Tremor (External Link)
Overview We propose a single site, double-blind, placebo-controlled, cross-over design. Drug will be administered in 75mg capsules with a target dose of 300 mg/day. Pregabalin will be titrated upward as …
Baylor Role:
Lead Sponsor